Abstract：Nasopharyngeal carcinoma NPC has an insidious onset and it exhibits a high degree of malignancy. More than 70%
of the patients are in middle or advanced stage at the time of initial diagnosis. Currently neoadjuvant chemotherapy combined with
concurrent chemoradiotherapy CCRT is used as the standard treatment for locally advanced NPC LA-NPC . Although it has a good
remission rate the risk of distant metastasis still exists in some patients. With the rapid development of immunotherapy immune
checkpoint inhibitors ICIs especially programmed death- 1 / programmed death ligand- 1 PD- 1 / PD-L1 blockade have made
breakthroughs in China. PD-1 inhibitors combined with chemotherapy have been used as the first-line treatment for recurrence and / or
metastatic NPC R/ M NPC . Meanwhile immunotherapy has made new breakthroughs in the treatment of LA - NPC and many
prospective clinical studies are underway. In this review we provide a comprehensive overview of the fundamentals of immunotherapy
for LA-NPC patients and important research findings in immunotherapy in LA-NPC based on published clinical data and ongoing
trials with the aim of providing insights for clinical practice and future clinical studies.
黄宁欣,何佳琦,罗海清. 免疫治疗在局部晚期鼻咽癌中的研究进展[J]. 肿瘤代谢与营养电子杂志, 2024, 11(4): 467-472.
Huang Ningxin, He Jiaqi, Luo Haiqing. Current progress of immunotherapy in locally advanced nasopharyngeal carcinoma. Electron J Metab Nutr Cancer, 2024, 11(4): 467-472.
